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The morphological features observed by Kerr, Wylie and Currie in 1972 define apoptosis, necrosis and autophagy. An appreciable number of
alternative systems do not fall neatly under these categories, warranting a review of alternative proteolytic machinery and its contribution to cell
death. This review aims to pinpoint key molecular features of serine protease-mediated pro-apoptotic signalling. The profile created will contribute
to a standard set of biochemical criteria that can serve in differentiating within cell death subtypes.
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The knowledge that cell death is an essential event in the life
of multi-cellular organisms has been around for more than
150 years. In 1972 Kerr et al., coined the term ‘apoptosis’ to
describe a distinct morphological pattern of physiologically
occurring cell death [1]. More recently, an increasing number of
‘alternative’ cell death systems are being described that do not
strictly conform to accepted apoptotic criteria, differing largely
in terms of the proteolytic machinery employed by the dying
cell. We are particularly interested in the roles of serine proteases
in that regard.
2. Apoptosis
Apoptosis is a carefully regulated process wherein there
exists an absolute requirement for controlled proteolytic
activation [2]. Almost since their discovery, activation of cys-
teinyl aspartate-specific proteases, the caspases, has been
considered synonymous with pro-apoptotic signalling [3,4].
Caspases are sequentially activated by two main mechan-
isms. In the intrinsic pathway, cytotoxic drugs or irradiation, for
example, can activate mitochondrial outer membrane perme-⁎ Corresponding author. Tel.: +353 91 495207; fax: +353 91 494596.
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doi:10.1016/j.bbamcr.2007.08.002ability (MOMP) triggering the release of apoptogenic factors.
Although the underlying mechanism of MOMP induction has
not been fully ascertained it is known to be regulated by
members of the Bcl-2 family (Fig. 11). Anti-apoptotic Bcl-2 and
Bcl-xl proteins block MOMP, whilst pro-apoptotic BH-3
domain only proteins; Bim and Bid promote MOMP through
activation of multi-domain proteins Bax and Bak [2,5,6].
Apoptogenic factors released include cytochrome c (cytC),
apoptosis inducing factor (AIF), SMAC (Second mitochondria-
derived activator of caspase)/DIABLO (Direct IAP-Binding
Protein with Low pI) and the serine protease Omi/HtrA2 [5]. The
role of cytC in cell death is well established, contributing to
caspase-9 activation through the formation of a cytosolic
apoptosome complex and the subsequent activation of cas-
pase-3 (Fig. 12) [7]. Caspase-3 targets a wide array of important
structural and regulatory proteins for cleavage such as DFF45
(DNA fragmentation factor-45)/ICAD (inhibitor of caspase-
activated DNase) and PARP (poly(ADP-ribose)polymerase)
(Fig. 13). [8]. The extrinsic pathway is triggered by ligation of
death receptors such as FAS/CD95 and TNF to natural ligands
present in the extracellular milieu. Subsequent recruitment of
pro-caspase-8 to the receptor via adaptor molecules autoproteo-
lytically activates caspase-8 that then cleaves caspase-3 directly
(Fig. 14) or indirectly through the activation of the intrinsic
pathway (Fig. 15) [2]. In the latter, caspase-8 cleaves the pro-
apoptotic BH3-only Bcl-2 family member, Bid which then
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Activation of either pathway ultimately results in the ordered
dismantling and demise of the cell.
However, caspase inhibition does not always prevent cell
death [9,10] and their targeted disruption does not always impair
apoptosis [11], therefore, roles for non-caspase proteases such as
the calpains, cathepsins and serine proteases in cell death have
recently attracted more interest [12,13]. Activation of calcium-
dependent calpain family members has been described in
caspase-independent cell death, autophagy and necrosis
[14,15]. The ubiquitously expressed μ and m-calpains promote
both apoptotic and survival signals in a cell and stimuli-specific
manner [15–17]. Calpains activated in response to the
accumulation of cytosolic calcium ions leads to the cleavage
of a number of substrates, including α-spectrin [18]. Cleavage ofFig. 1. Schematic illustrating the points of involvement of serine proteases in the apo
transmembrane potential that can occur before, during or after MOMP. Numbers refe
there. Serine proteases are highlighted in yellow. Where the molecular weight of the s
denoted as pX. Endonucleases are outlined in red; MnEndo, manganese-dependentthe pro-caspases-7, and -8 results in their inactivation and
negatively impacts upon apoptotic events [19] whereas cleavage
of pro-caspase-9, -12 and Bcl-xl promotes apoptosis [19,20].
Calpain-mediated Bid cleavage has been demonstrated as an
essential early caspase-independent event during cisplatin-
induced cell death in human melanoma cells, characterising
one of two activated cell death pathways; the other involving
Bak modulation [21]. Cathepsins which are cysteine proteases
from the lysosomal compartment have also been implicated in a
number of cell death processes [22]. Ligation of death receptors
like the TNFα (Tumour Necrosis Factor-α) receptor can induce
the release of cathepsin B into the cell cytosol leading to the
activation of caspase-dependent and independent cell death
[22–24] and cathepsins D and B have been implicated in
camptothecin-induced death of liver cancer cells [25].ptotic cascade. ΔΨm indicates change in dissipation of the mitochondrial inner
r to pathways discussed in text and correlate to the superscript numbers assigned
erine protease involved is known, it is given (e.g. p16) where not the protease is
endonuclease; EndoX, yet to be identified endonuclease.
1493A.R. O’Connell, C. Stenson-Cox / Biochimica et Biophysica Acta 1773 (2007) 1491–1499Cathepsins are released into the cytosol prior to mitochondrial
membrane-potential changes [26,27] and can activate caspases
indirectly through cleavage of Bid [27,28].
The involvement of serine proteases within the apoptotic
machinery is the least well understood of the non-caspase
proteases and only a limited number of pro-apoptotic serine
proteases have been isolated. This is in contrast to the large
amount of data expounding their contribution to various
apoptotic events. It is evident that the established apoptosis-
associated serine proteases cannot be responsible for all of the
potential serine protease-mediated functions observed to date.
This implies that there is much more to learn regarding the
influence and identity of serine proteases within apoptosis. In
this review we summarise the current data pertaining to serine
proteases in the initiation and execution phases of apoptosis.
3. Granzymes and cell death
Granzymes are serine proteases found exclusively in the
granules of activated cytotoxic T lymphocytes (CTL) and
natural killer (NK) cells and play a critical role in eliminating
virally infected and malignant cells [29,30]. Cytotoxic granules
also contain a pore-forming protein, perforin, which upon
recognition and contact with target cells, mediate the delivery of
the granzymes into the intermembrane space of the target cells
[31]. Granzyme A and B are the two most abundant and
extensively studied members of the granzyme family and studies
in cytotoxic lymphocytes (CL) from knockout mice have
confirmed that they independently and synergistically induce
cell death through distinct apoptotic pathways [32].
4. Granzyme B
Granzyme B (Gr B) is a 32-kDa protease that cleaves sub-
strates following an aspartate residue, thus exhibiting substrate
specificity similar to that of caspase family members. It is well
established that Gr B can engage multiple components of the
apoptotic machinery in target cells triggering direct and indirect
activation of caspases and the cleavage of a number of pro-
apoptotic proteins (Fig. 18) [29–32]. Gr B can directly process
and activate pro-caspases-3 and -7 and can induce a partial
cleavage of caspase-8 and -10 [33–35]. The activated caspase-3
can then process pro-caspase-9, -2, and -6 or complete the Gr
B-initiated maturation of caspase-8 and -10 [34]. Gr B also
triggers indirect caspase activation through cleavage of the
BH3-domain only protein Bid leading to MOMP initiation and
cytochrome c release [36–38]. Cells deficient in Bid are
resistant to Gr B-induced apoptosis, and continue to proliferate
in long-term survival assays (Fig. 17) [38]. More recently, the
Bcl-2 family member Mcl-1 has also been identified as a Gr B
substrate that when cleaved allows the release of Bim and
induction of MOMP [39,40]. Gr B can also induce features
associated with apoptosis through direct cleavage of specific
proteins. For instance, Gr B mediates cleavage of the Rho-
regulated kinase Rock II, a regulator of actomyosin contraction
that results in membrane blebbing and Gr B shares the caspase-
3 substrate; DFF45/ICAD [30]. Caspase-3 mediates genomicintegrity largely through proteolytic inactivation of DFF45/
ICAD that acts as an endogenous inhibitor of a DNase (DFF40/
CAD) (Fig. 13) [41]. Gr B has been shown to process DFF45
in vitro and in vivo at the caspase-3 cleavage site, and to
mediate DNA fragmentation in the absence of caspase-3
activity (Fig. 110) [42,43].
The relative importance of the direct caspase pathway com-
pared to the Bid pathway and cleavage of other pro-apoptotic
substrates during CL-mediated killing has been the subject of
much debate. Central to this has been the assumption that mouse
and human Gr B possess identical substrate specificities and as a
result experiments have used Gr B from either human or murine
sources inter-changeably across species. However, it has now
been clearly demonstrated that mouse and human Gr B exhibit
distinct specificity and different abilities to engage with the
caspase or Bid apoptotic machinery [35,44,45]. Whereas both
human andmouse Gr B process pro-caspase-3, cleaving species-
specific caspase more efficiently than unmatched substrate,
mouse Gr B fails to cleave Bid, pro-caspase-8 and ICAD, even
when the human equivalent does so efficiently under the same
experimental conditions suggesting that Bid is not a critical
mediator of mouse Gr B-mediated cytotoxicity. Complimenting
these studies are the observations that serpins prevent granzyme-
induced death in a species-specific manner and that human and
mouse Gr B serpins are not evolutionarily conserved [45,46].
5. Granzyme A
Granzyme A (Gr A) is a highly selective tryptic protease that
triggers a rapid form of cell death that exhibits all of the mor-
phological features associated with apoptosis: membrane
blebbing, chromatin condensation and nuclear fragmentation
[47]. However, Gr A does not activate caspase family members,
caspase inhibition fails to prevent Gr A-induced death and Bcl-2
overexpression does not inhibit Gr A cytolysis [47,48]. In
addition Gr A does not cleave many key caspase targets
including lamin B and PARP [47]. During cell death Gr A
rapidly accumulates in the nucleus, where it appears to target the
nuclear envelope protein lamin, the chromatin structural protein
Histone H1 and DNA [49–52]. Indeed, DNA damage is a
defining characteristic of the caspase-independent Gr A cell
death pathway, marked by single-stranded nicks resulting in
large DNA fragments [52]. A 270–440 kDa multi-protein
complex, known as the SET complex, has recently been
identified as being responsible for Gr A-mediated DNA damage
[53,54]. Nucleus translocation of the SET complex from the
cytosol is an early event in GrA-mediated cell death. The SET
complex is comprised of three GrA substrates-the nucleosome
assembly protein SET (putative HLA-associated protein II,
template-activating factor (TAF)-1, or I2
PP2A), the DNA bending
protein HMG-2, and the base excision repair endonuclease
Ape1. Cleavage of these substrates by GrA destroys all of their
known functions [55,56]. The complex also contains a 25-kDa
Mg2+-dependent DNase; NM23-H1 (GzmA-activated DNase)
or GAAD, whose activity is normally held in check by its
inhibitor SET (IGAAD). When SET is cleaved it allows the
endonuclease, together with an exonuclease TREX1 that binds
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regulation, at the level of the mitochondrion, proteolytically
active Gr A triggers a rapid and sustained increase of
intracellular reactive oxygen species (ROS) and a concomitant
loss of transmembrane potential that continues in the presence of
caspase inhibition and Bcl-2 overexpression [48]. Gr A does not
cleave Bid and despite the loss of transmembrane potential, the
outer mitochondrial membrane remains intact preventing the
release of apoptogenic factors such as cytochrome c, AIF,
EndoG. Although the exact molecular mechanisms responsible
for Gr A-mediated mitochondrial damage are undetermined, the
affects are direct, associated with opening of the PT pore, and are
neither cell-type nor species specific. Functionally Gr A-induced
ROS accumulation has been shown to trigger the translocation of
the SET complex, from the cytoplasm to the nucleus [47,48].
The mechanism by which this occurs remains to be resolved.
6. Omi and cell death
Omi is a mammalian serine protease belonging to the HtrA
(high temperature requirement A) protease/chaperone family,
members of which are essential in the survival of high tem-
peratures or oxidative stress. Omi can be catalytically processed
during apoptosis and released from the mitochondria whereupon
it binds to IAPs neutralizing their inhibitory action upon
caspases (Fig. 16) [58]. Omi also possesses a caspase-
independent pro-apoptotic serine protease activity (Fig. 16);
deletion of a tryspin-like domain results in partial inhibition of
apoptosis [59] and cell death induced by Omi overexpression
occurs under caspase inhibiting conditions and in APAF-1 and
caspase-9 null cells [60,61].
Omi's relevance in cell death has been called into question
however, with data from recent gene knockout studies and the
mnd2 (motor neuron degeneration 2) mouse implying that
although Omi can bind IAPs, it does not play a role in promoting
cell death, but rather acts as a protease to remove misfolded
proteins in the mitochondria. Studies in the mnd2 mouse, a
disease characterised by altered gait, muscle wasting and early
death, has shown that Omi can exert cell survival and death. In
this model, a missense mutation in the protease domain of Omi
changes an evolutionary conserved serine to a cysteine
abrogating the serine protease activity without affecting the
ability to interact with IAPs effectively creating an in vivo ‘loss-
of-function model’ [62]. At the cellular level striated neurons
exhibit both necrotic and apoptotic features including nuclear
condensation, DNA laddering and early degeneration of
mitochondria. Mouse Embryonic Fibroblasts (MEFs) from
mnd2 mice demonstrate increased sensitivity to cell death
correlated to increased susceptibility to induce mitochondria
permeability transition (MPT) compared to wild type cells.
Given Omi's structural similarity to the bacterial HtrA protease/
chaperone family, it is hypothesised that under normal
conditions Omi acts as a stress sensor, preventing the
accumulation ofmisfolded and damaged proteins and preserving
mitochondrial membrane integrity and function (Fig. 16). This
hypothesis has been strengthened by studies in mice entirely
lacking expression of HtrA2/Omi due to the targeted homozy-gous deletion of the Prss2 gene [63]. The appearance of these
animals is akin to the mnd2 mice, characterised by a
Parkinsonian-like phenotype and early death resulting from the
loss of striatal neurons. The similarity between knockout
animals that lack all expression of Omi to that of the mnd2
mouse, exhibiting loss of protease activity only, raises questions
about the physiological significance of Omi in apoptosis
regulation. Omi's IAP binding appears to be a highly redundant
function, at least in mice, for which mediation by other proteins
is necessary.
7. Apoptotic protein 24 (AP24)
AP24 is a 24-kDa serine protease with an elastase-like
activity that triggers oligonucleosomal DNA fragmentation [64].
This activity has been observed in the cytosol and nucleus of
tumour cell lines undergoing apoptosis, from which it has been
partially purified [65]. Activation of AP24 occurs in response to
a variety of stimuli including TNF, UV irradiation and
chemotherapeutic agents [66,67]. Inhibition of protein synthesis
does not affect AP24 activation indicating that the protein is
expressed constitutively in either an active sequestered, or an
inactive form, prior to exposure to an apoptotic stimulus [67].
AP24 induces DNA fragmentation indirectly, by inactivating the
serpin, leukocyte elastase inhibitor (LEI), through translational
modification and converting it to an endonuclease (L-DNase II)
[64,68]. The resultant DNase II translocates to the nucleus and
subsequently induces DNA degradation. Regulators of AP24
activation include sphingomyelin and calcium/calmodulin-
dependent kinase II (CaMKII) and overexpression of Bcl-2
inhibits AP24 activity in HL-60 cells [65,69–71].
8. Urokinase-type plasminogen activator (uPA)
The urokinase plasminogen activator (uPA) is a 53-kDa
trypsin-like serine protease which converts the zymogen
plasminogen into active plasmin, a broad spectrum protease
[72]. uPA is secreted as a pro-form, and its activation is mediated
by its receptor uPAR. In-vivo, the catalytic activity of uPA is
inhibited by its natural inhibitor plasminogen activated inhibitor
(PAI-2) [72,73]. uPA has been largely implicated in metastasis
and the invasion of cancer cells and a relationship with cathepsin
B has also been suggested. RNA interference-mediated
simultaneous down-regulation of uPAR and cathepsin B have
been shown to induce caspase-8-mediated apoptosis in human
glioma cells which is also accompanied by nuclear translocation
of AIF (Apoptosis Inducing Factor) [74].
9. Serine proteases and the apoptotic mitochondrion
A role for serine proteases in early mitochondrial-related
events has been implied in a number of apoptotic programs, even
at the level of MOMP induction. For example, a cell death
program activated in monocytes deprived of IL-3 and in ER
stressed R6 fibroblasts remains active when caspases are
inhibited [9]. Co-treatment of the stressed cells with a serine
protease inhibitor prevents apoptosis-associated pyknosis,
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alone does not. Significantly, cytC release is also prevented by
the serine protease inhibition implying a mechanism involving
mitochondrial membrane damage. Where exactly serine pro-
teases might function in mitochondrial permeability induction
was not shown in this study, however evidence from other
models supports a potential relationship between serine protease
activities and Bcl-2 family members (Fig.11). For instance,
Taxol-induced cell death in human breast carcinoma cells can be
prevented by a chymotrypsin-like inhibitor that concomitantly
blocks Bcl-2 phosphorylation, a post-translational modification
required for its full and potent anti-apoptotic function [75]. Also,
a trypsin-like inhibitor prevents cytC release in ethanol-induced
hepatoma cell death, whilst preventing cleavage of Bcl-2 and
Bcl-xl proteins [76].
10. Serine proteases and the caspases
Serine proteases can mediate caspase activation through post-
mitochondrial events. For example, apoptosome-stimulated
caspase-9 processing is preventable by serine protease inhibition
[77], Gr B can cleave pro-caspase-3 (Fig. 18) [38] and we and
others have shown that inhibition of chymotrypsin-like
proteases prevents caspase-3 activation [9,10].
We have also recently characterised three putative serine
proteases involved in caspase-dependent and independent cell
death programmes. P16 is a 16-kDa chymotrypsin-like protein
species that is found basally active in acute myleogenous
leukaemic cells and whose activity is specifically induced in a
time and concentration-dependent manner by the protein
kinase inhibitor; staurosporine. Detection and characterisation
of p16 was enabled by labelling with a fluorescein-conjugated
cell permeable compound that covalently binds to the active
centres of chymotrypsin-like proteases [10]. We hypothesise
that p16 is a primary mediator of a stauroporine-triggered
serine protease-mediated cell death pathway that occurs in
parallel, but independently to caspase-controlled systems in
HL-60 cells. The novel pathway accumulates in a loss of cell
volume, nuclear condensation and oligonucleosomal DNA
fragmentation (Fig 19) [10].
Prior to our study several groups had reported staurosporine-
triggered caspase-independent progression to cell death in a
range of cell types including peripheral T lymphocytes, bovine
lens epithelial and HL-60 cells, but the identity of the molecules
involved and nature of the non-caspase-mediated events were
unresolved [78,79]. Our initial observation showed that the pan-
caspase inhibitor z-VAD.FMK did not prevent all apoptotic
features activated in staurosporine-treated HL-60 cells, however
it did specifically abrogate staurosporine-induced caspase-3
activation and cleavage of PARP. To determine the putative non-
caspase protease(s) responsible for the z-VAD-FMK resistant
apoptotic events, the effects of a panel of cell permeable protease
inhibitors were assessed. Results demonstrated that only
chymotrypsin-like inhibitors and a pan-serine protease inhibitor
could significantly reduce the activated cell shrinkage, nuclear
condensation and oligonucleosomal DNA. In addition a rise
in staurosporine-induced chymotrypsin-like proteolytic activitywas detectable and completely abrogated by a serine protease
inhibitor administrated at the same concentration levels that also
prevented the apoptotic cellular and nuclear events. Serine
protease inhibition did not prevent the z-VAD-FMK-dependent
caspase activation or PARP cleavage suggesting that serine
proteases are activated in parallel but independently to caspases
[10]. It has been demonstrated that zVAD-FMK can generate
fluoracetate in cells, which is directly toxic by inhibiting
aconitase, therefore cell death in the presence of zVAD-FMK
may, at times, be due to inhibition of the TCA cycle, rather than
activation of other proteases [80,81]. However, this was not the
case in our study, where cell treatment with a range of z-VAD-
FMK concentrations alone did not induce apoptotic or
secondary necrotic features nor was there an additive or
synergistic rise in apoptotic features observed when adminis-
tered prior to staurosporine.
We have also recently characterised the caspase-dependent
activation of the two chymotrypsin-like proteases, p50 and p60
that appear to mediate nuclear events during Jurkat T cell
apoptosis (Fig 111) [82]. P60 is constitutively active species
whose activity is increased in response to staurosporine whilst
p50 appears active only in the presence of the staurosporine.
Caspase activation is a prequisite for activation of these proteins
after which they can mediate specific caspase-regulated events,
in particular the late stage morphological features of apoptosis
including nuclear fragmentation and condensation, as well as
DNA fragmentation. This is further supported by the observa-
tion that the serine proteases are activated within the cytosol and
translocate into the nucleus as apoptosis progresses [82].
Serine proteases may also act upon caspase-independent
endonucleases, for example, chymotrypsin-like proteases are
required for the activation of a manganese-dependent acidic
endonuclease during PBOX-6-induced cell death of Chronic
Myelogenous Leukaemic cells where oligonucleosomal DNA
fragmentation takes place in the absence of caspase and CAD
activation (Fig. 19) [83].
11. Serine proteases and receptor-mediated apoptosis
Serine proteases do not appear to be involved in early events
of receptor-mediated death however, cytosolic serine protease
activity isolated from Fas-treated Jurkat T cells can induce DNA
fragmentation implying a role at a later stage [84]. Perhaps more
significantly however, is the apparent requirement of serine
proteases for optimal signalling in an alternative pathway of
TNFR1 associated death domain protein (TRADD)-induced
apoptosis [85]. Overexpression of the TRADD core death
domain containing a nuclear import sequence results in a
nuclear localised protein that kills via a caspase-9 and serine
protease-dependent process, differentiating from the typical
cytosolic caspase-8-dependent route for which caspase activa-
tion appears sufficient.
12. Serpins, regulation of serine proteases and cell death
Regulation of activated proteases is essential in the main-
tenance of normal cellular function and homeostasis. The
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specific endogenous serine protease inhibitors, the serpins.
Members of the serpin superfamily are known regulators of
intracellular proteolysis and have been implicated in regulating
the apoptotic process through the inhibition of cytosolic
proteases [86]. The majority of serpins identified to date behave
as pseudo-substrates inhibiting activated protease through
irreversible complex formation. Proteases bind to a ‘reactive
centre loop’, inducing a conformational change in the serpin
that serves to stabilise the complex rendering it irreversible.
Specificity is dictated primarily through cleavage between two
specific amino acids P1 and P2 within the reactive centre [87].
The viral serpin, cytokine response modifier A (CrmA) was
originally discovered through its ability to prevent interleukin-1
processing by inhibiting caspase-1 [88,89]. CrmA has since
been shown to inhibit activated caspase-8 and prevent both
Fas- and TNF-induced apoptosis [90–92]. Significantly, CrmA
is also an inhibitor of Gr B displaying an Asp at the P1
position in the reactive center loop [88,93]. CrmA can abro-
gate Gr B-mediated apoptosis and expression of CrmA renders
target cells resistant to Gr B-induced cell death by CLs [90]. The
cytosolic serpin protease inhibitor 9 (PI-9) is the only known
human protein that can specifically inhibit granzyme B activity
and exhibits a greater potency than CrmA [94]. Although it
shares many similarities to the viral-encoded CrmA, PI-9
contains a Glu rather than Asp at the crucial P1 position and
this appears to directly affect its specificity. Cells expressing PI-
9 are protected against Gr B-induced apoptosis, however PI-9
does not confer resistance to Fas-induced apoptosis. The Glu at
P1 confers specificity for Gr B only and the serpin is a poor
substrate for caspases [95]. It has been postulated that the
inhibition of Gr B-mediated, but not Fas-induced apoptosis by
PI-9 may serve to protect CLs from apoptosis following
cytotoxic cell degranulation whilst allowing the deletion of
cells from the immune system via the Fas pathway [95].
Furthermore, the in vivo distribution of PI-9 mRNA demon-
strates an expression pattern restricted largely to the immune
tissue, with expression primarily in the lymphocytes. The
restricted expression profile may explain why cytotoxic cells are
not damaged by their ownGr B during elimination of target cells,
with CL synthesising their own serpins that bind and neutralize
mis-localised or mis-directed Gr B [95]. A comparable
mechanism to protect CTL from self-inflicted injury can also
be found in the mouse. Mice deficient in the murine Gr B
inhibitor Serine Protease Inhibitor 6 (Spi6) show increased
sensitivity to infection with Listeria monocytogenes [96].
Significantly, CTL from the Spi6 knockout animals showed a
breakdown in cytotoxic granules integrity, increased cytoplas-
mic Gr B levels, and increased rates of apoptosis suggesting that
Spi6 prevents CTL damage triggered by Gr B-mediated
breakdown of cytotoxic granules [96]. PI-9 and Spi6 have
recently been shown to prevent granzyme-induced death in a
species-specific manner [46]. Whereas high expression of either
PI-9 or Spi6 prevent apoptosis induced by human Gr B only Spi-
6, and not PI-9, that is capable of inhibiting murine Gr B. Tumor
cells may also utilize expression of serpins to render them-
selves more resistant to CTL-mediated apoptosis and evadethe immune system, for example human malignant lymphomas
express PI-9 [97,98] and murine malignant cells have been
found to express Spi6 [99]. Other members of the serpin family
such as PAI-2 (plasminogen activator inhibitor 2) and PN-1
(protease nexin 1) and Spi2A have also been implicated in the
regulation of cell death [86] and as already mentioned the serine
protease AP24 induces DNA fragmentation indirectly by
inactivating the serpin leukocyte elastase inhibitor (LEI).
AP24 induces a post-translational modification resulting in a
molecular weight shift, loss of LEI elastase-inhibiting activity
and appearance of L-DNase II activity [64,100].
13. Conclusions and future perspectives
Serine protease involvement in apoptosis is a somewhat
controversial topic largely due to the lack of appropriate
biological tools with which to study them and the relatively
small number of pro-apoptotic serine proteases identified to
date. However a preponderance of evidence over the last decade
continues to imply their involvement in cell death where they
demonstrate a range of molecular mechanisms, specificity and
regulation. It is to be expected that advances in biochemistry
and proteomics can be harnessed to extract and characterise
novel pro-apoptotic serine proteases that are responsible for
supporting and propagating caspase and non-caspase-mediated
cell death programs.
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